Vancomycin Enema denied as experimental or investigational by Humana?

Humana's specific coverage criteria for vancomycin enema are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Vancomycin Enema as Experimental

Humana's "experimental or investigational" denial category is applied when the insurer's medical policy concludes that a treatment lacks sufficient evidence under its internal evidence-grading standard. For vancomycin enema, this denial typically arises because vancomycin enema is not an FDA-approved finished drug product in the conventional sense — it is a compounded preparation used in specific clinical scenarios for Clostridioides difficile (C. diff) infection, particularly when conventional oral routes are not feasible.

An "experimental" denial for a compounded preparation used in a serious, life-threatening infection is strongly challengeable. Infectious disease society guidelines — including those from organizations such as the Infectious Diseases Society of America (IDSA) — address the use of vancomycin administered via enema or retention enema in C. diff patients with anatomical barriers to oral delivery. Citing that guideline support is central to this appeal.

## Your Federal Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): File within the timeframe on the denial notice. Request the specific evidence-review standard Humana applied and the exact policy version used — you are entitled to this under ERISA.
• Expedited review: Given the acuity of C. diff infections, expedited internal and external review may be warranted.
• External review: If the internal appeal fails, file for IRO review within approximately four months. External reviewers assess whether the treatment meets the general standard of medical evidence — not just Humana's internal threshold — and frequently overturn experimental denials for treatments with guideline-body support.

## Documentation to Gather

1. Guideline citations: A copy of or reference to the relevant IDSA or other applicable infectious disease guideline that addresses vancomycin enema for C. diff in patients where oral delivery is not feasible. The prescriber should cite the specific guideline organization and section. 2. Clinical necessity for this route: Chart documentation of the anatomical or clinical reason (ileus, diversion, failed oral absorption, etc.) establishing why the enema route is necessary. 3. Peer-reviewed literature: The prescriber or a specialist can identify published case series or clinical studies supporting this use — without asserting specific statistics in the appeal, simply note that peer-reviewed published evidence supports the approach and attach it as an exhibit. 4. Prescriber letter of medical necessity: A detailed letter from the treating infectious disease specialist or gastroenterologist addressing Humana's specific experimental-denial criteria and explaining why this treatment is consistent with accepted medical practice.

## Criteria-Mapping Strategy

Request Humana's current experimental/investigational coverage policy for vancomycin enema or compounded vancomycin preparations. For each stated criterion (e.g., guideline support, peer-reviewed evidence, FDA status of comparator), provide a direct documentary response. Frame the appeal around the IDSA guideline organization's position and the patient's specific clinical indication as the basis for overriding the experimental classification.